First insights into Pharmaxis’ Phase I safety data of its anti-fibrotic LOXL2 inhibitor programme, in which Synairgen retains a 17% interest in all future financial payments, shows that Pharmaxis is on track to license this asset in H2 2018. Pharmaxis informed potential partners attending the recent BIO 2018 conference in Boston on data emerging from the Phase I clinical studies, which have demonstrated a best in class profile and clean safety profile. The Phase I trial and Phase II-ena
14 Jun 2018
First insight into Pharmaxis LOXL2 Phase I data
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
First insight into Pharmaxis LOXL2 Phase I data
Synairgen plc (SNG:LON) | 6.7 0 0.0% | Mkt Cap: 13.6m
- Published:
14 Jun 2018 -
Author:
Mark Brewer -
Pages:
4
First insights into Pharmaxis’ Phase I safety data of its anti-fibrotic LOXL2 inhibitor programme, in which Synairgen retains a 17% interest in all future financial payments, shows that Pharmaxis is on track to license this asset in H2 2018. Pharmaxis informed potential partners attending the recent BIO 2018 conference in Boston on data emerging from the Phase I clinical studies, which have demonstrated a best in class profile and clean safety profile. The Phase I trial and Phase II-ena